Gilead Sciences (GILD) 108.22 $GILD
Jim Cramer's 'Mad Money' Recap: This Is Why Apple Rules
at The Street - Wed Sep 10, 7:10PM CDT
Apple is one of a number of innovators whose shares have risen and rewarded shareholders, Cramer says.
PDL BioPharma Sees Higher-than-Expected Revenues in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 5:40PM CDT
PDL BioPharma (PDLI) announced that it expects to generate revenues of roughly $165 million in the third quarter of 2014.
Final Glance: Biotechnology companies
AP - Wed Sep 10, 5:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Spectrum Pharmaceuticals to Advance Neutropenia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 4:20PM CDT
Spectrum Pharmaceuticals (SPPI) announced its intention to initiate a phase III study on SPI-2012 next year.
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 2.20%
Comtex SmarTrend(R) - Wed Sep 10, 3:36PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.23. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $106.98 on volume of 11.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Gilead Sciences to Potentially Pullback After Gaining 2.20% Yesterday
Comtex SmarTrend(R) - Wed Sep 10, 3:35PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.23. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $106.98 on volume of 11.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Auxilium Pharmaceuticals to Restructure, Cut Jobs by 30% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:35PM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) announced certain restructuring steps following a comprehensive assessment of Auxilium Pharma's product portfolio in a bid to lower operating costs and drive growth.
Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog
Maharathi Basu - Zacks Investment Research - Wed Sep 10, 3:30PM CDT
Emergent BioSolutions (EBS) secured a federal contract worth up to $29 million.
Myriad Genetics Posts Encouraging myPath Melanoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 2:00PM CDT
Myriad Genetics, Inc. (MYGN) reported favorable results from a pivotal clinical utility study of its myPath Melanoma test.
Stocks Turn Higher After Soft Start; U.S. Silica Jumps
at Investor's Business Daily - Wed Sep 10, 12:25PM CDT
Stocks turned higher in early afternoon trade Wednesday after a soft open. The Nasdaq led the way, rising 0.5%. The Dow Jones industrial average and S&P 500 added 0.1% each. Volume on the NYSE and Nasdaq was tracking 5% to 10% higher than Tuesday's...
Midday Glance: Biotechnology companies
AP - Wed Sep 10, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).
Stocks Up At Midday; Alexion Leads Biotech Rebound
at Investor's Business Daily - Wed Sep 10, 10:54AM CDT
Stocks were slightly higher at midday Wednesday in a seesaw session. The Nasdaq was up 0.2%, while the Dow Jones Industrial average and the S&P 500 each rose 0.1%. Volume was 10% higher on the Nasdaq and 4% higher on the NYSE compared to the same...
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 10, 10:17AM CDT
AbbVie's (ABBV) collaboration agreement with Infinity Pharmaceuticals (INFI) was one of the top stories in the biotech sector last week.
Gilead Sciences (GILD) Approaches New Upside Target of $108.39
Comtex SmarTrend(R) - Wed Sep 10, 9:34AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $105.73 today and have reached the first resistance level of $107.14. Investors may be interested in a cross of the next upside pivot targets of $108.39 and $111.05.
Early Glance: Biotechnology companies
AP - Wed Sep 10, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
ERBA Diagnostics (ERB) in Focus: Stock Up 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 8:39AM CDT
ERBA Diagnostics, Inc. (ERB)was a big mover last session, as its shares rose nearly 7% on the day.
Burlington Stores, Quiksilver, Hospira, Mylan and Gilead Sciences highlighted as Zacks Bull and Bear of the Day
PR Newswire - Wed Sep 10, 8:30AM CDT
Zacks Equity Research highlights Burlington Stores, Inc. (NYSE:BURL-Free Report) as the Bull of the Day and Quiksilver, Inc. (NYSE:ZQK-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Hospira (NYSE:HSP-Free Report), Mylan (Nasdaq:MYL-Free Report) and Gilead Sciences (Nasdaq:GILD-Free Report).
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 8:00AM CDT
Peregrine Pharmaceuticals, Inc. (PPHM) reported a net loss of 8 cents per share in the first quarter of fiscal 2015.
Jim Cramer's 'Mad Money' Recap: This Is Why Apple Rules
at The Street - Wed Sep 10, 7:10PM CDT
Apple is one of a number of innovators whose shares have risen and rewarded shareholders, Cramer says.
PDL BioPharma Sees Higher-than-Expected Revenues in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 5:40PM CDT
PDL BioPharma (PDLI) announced that it expects to generate revenues of roughly $165 million in the third quarter of 2014.
Final Glance: Biotechnology companies
AP - Wed Sep 10, 5:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Spectrum Pharmaceuticals to Advance Neutropenia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 4:20PM CDT
Spectrum Pharmaceuticals (SPPI) announced its intention to initiate a phase III study on SPI-2012 next year.
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 2.20%
Comtex SmarTrend(R) - Wed Sep 10, 3:36PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.23. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $106.98 on volume of 11.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Gilead Sciences to Potentially Pullback After Gaining 2.20% Yesterday
Comtex SmarTrend(R) - Wed Sep 10, 3:35PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $105.76 to a high of $108.23. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $106.98 on volume of 11.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Auxilium Pharmaceuticals to Restructure, Cut Jobs by 30% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:35PM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) announced certain restructuring steps following a comprehensive assessment of Auxilium Pharma's product portfolio in a bid to lower operating costs and drive growth.
Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog
Maharathi Basu - Zacks Investment Research - Wed Sep 10, 3:30PM CDT
Emergent BioSolutions (EBS) secured a federal contract worth up to $29 million.
Myriad Genetics Posts Encouraging myPath Melanoma Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 2:00PM CDT
Myriad Genetics, Inc. (MYGN) reported favorable results from a pivotal clinical utility study of its myPath Melanoma test.
Stocks Turn Higher After Soft Start; U.S. Silica Jumps
at Investor's Business Daily - Wed Sep 10, 12:25PM CDT
Stocks turned higher in early afternoon trade Wednesday after a soft open. The Nasdaq led the way, rising 0.5%. The Dow Jones industrial average and S&P 500 added 0.1% each. Volume on the NYSE and Nasdaq was tracking 5% to 10% higher than Tuesday's...
Midday Glance: Biotechnology companies
AP - Wed Sep 10, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).
Stocks Up At Midday; Alexion Leads Biotech Rebound
at Investor's Business Daily - Wed Sep 10, 10:54AM CDT
Stocks were slightly higher at midday Wednesday in a seesaw session. The Nasdaq was up 0.2%, while the Dow Jones Industrial average and the S&P 500 each rose 0.1%. Volume was 10% higher on the Nasdaq and 4% higher on the NYSE compared to the same...
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 10, 10:17AM CDT
AbbVie's (ABBV) collaboration agreement with Infinity Pharmaceuticals (INFI) was one of the top stories in the biotech sector last week.
Gilead Sciences (GILD) Approaches New Upside Target of $108.39
Comtex SmarTrend(R) - Wed Sep 10, 9:34AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $105.73 today and have reached the first resistance level of $107.14. Investors may be interested in a cross of the next upside pivot targets of $108.39 and $111.05.
Early Glance: Biotechnology companies
AP - Wed Sep 10, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
ERBA Diagnostics (ERB) in Focus: Stock Up 7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 8:39AM CDT
ERBA Diagnostics, Inc. (ERB)was a big mover last session, as its shares rose nearly 7% on the day.
Burlington Stores, Quiksilver, Hospira, Mylan and Gilead Sciences highlighted as Zacks Bull and Bear of the Day
PR Newswire - Wed Sep 10, 8:30AM CDT
Zacks Equity Research highlights Burlington Stores, Inc. (NYSE:BURL-Free Report) as the Bull of the Day and Quiksilver, Inc. (NYSE:ZQK-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Hospira (NYSE:HSP-Free Report), Mylan (Nasdaq:MYL-Free Report) and Gilead Sciences (Nasdaq:GILD-Free Report).
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 8:00AM CDT
Peregrine Pharmaceuticals, Inc. (PPHM) reported a net loss of 8 cents per share in the first quarter of fiscal 2015.
